Answers are grounded in this paper and cite their sources.
Construction of stimuli-responsive theranostic nanoagents that can increase the accuracy of imaging diagnosis and boost the therapeutic efficacy has been demonstrated for a promising approach for diagnosis and treatment of cancer. Herein, we constructed a novel theranostic agent with Co–P nanocomposites as core, mesoporous silica as shell, and manganese dioxide (MnO 2 ) nanosheets as gatekeeper, which have been employed for pH-activatable T 1 /T 2 dual-modality magnetic resonance imaging (MRI)-guided chemotherapeutical and photothermal combination anticancer therapy in vitro and in vivo. Co–P core-enabled theranostic platform could be applied for both photothermal therapy and T 2 -weighted MRI in the normal circulation owing to its strong near-infrared absorbance and intrinsic magnetic properties. In the acidic environment of tumors, MnO 2 cap could be dissolved into Mn 2+ ions to not only realize pH-responsive on-demand drug release but also activate T 1 -weighted MRI contrast enhancement. Such T 1 /T 2 dual-mode MR imaging provides further comprehensive details and accurate information for tumor diagnosis, and the on-demand chemo-photothermal synergetic therapy greatly improved the therapeutic effectiveness and effectively mitigated side effects. These findings demonstrate that Co–P@mSiO 2 @DOX–MnO 2 are promising as pH-responsive theranostic agents for tumor diagnosis and treatment, and stimulate interest in exploration of novel stimuli-responsive theranostic nanoagents which posssess good potential for clinical application in the future.
No takes yet. Share an insight, caveat, or question.
Jin et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: